ACADM and fatty liver disease: The administration of estrogens reverses the hepatic steatosis, by reducing the expression of genes involved in DNL (e.g., Fasn, fatty acid synthase; Acaca, acetyl-CoA carboxylase α; Scd-1, stearoyl-CoA desaturase-1) and fatty acid uptake (e.g., Adrp, adipocyte differentiated regulatory protein) (302, 304) and by restoring the expression of enzymes involved in FA oxidation (e.g., Cat, catalase; Mcad, medium-chain acyl-CoA dehydrogenase) (305).